MNKD, operating in its industry, demonstrates strong financial metrics in debt and liquidity but fails Shariah compliance due to an interest income ratio of 14.73%, exceeding the 5% threshold across major standards. The company's biopharmaceutical focus is permissible, with no non-compliant business activities identified. However, index exclusion underscores the need for income purification. Overall, while purification allows limited investment, the stock is classified as non-compliant based on index criteria.